Literature DB >> 2398542

CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells.

I Sekigawa1, S M Chamow, J E Groopman, R A Byrn.   

Abstract

Recombinant soluble CD4 (rCD4) has been shown to be an effective inhibitor of human immunodeficiency virus type 1 (HIV-1) and HIV-2 infection of lymphoid cells in vitro. In this report, we characterized the effects of rCD4, the V1V2 fragment of CD4, and the immunoadhesin CD4-immunoglobulin G on syncytium formation between lymphoid cells infected by HIV-1 or HIV-2 and uninfected cells. All three molecules blocked HIV-1-mediated syncytium formation, but only CD4-immunoglobulin G blocked HIV-2-mediated syncytium formation. rCD4 and the V1V2 fragment of CD4 enhanced HIV-2-mediated syncytium formation. These results suggest that the process of cell fusion is significantly different between HIV-1- and HIV-2-infected cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2398542      PMCID: PMC248017     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  HIV infection is blocked in vitro by recombinant soluble CD4.

Authors:  R A Fisher; J M Bertonis; W Meier; V A Johnson; D S Costopoulos; T Liu; R Tizard; B D Walker; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

2.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

Authors:  A Traunecker; W Lüke; K Karjalainen
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

3.  A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.

Authors:  E A Berger; T R Fuerst; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

4.  Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4.

Authors:  A Peterson; B Seed
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

5.  Effect of recombinant soluble CD4 on human peripheral blood lymphocyte responses in vitro.

Authors:  M A Liu; T Liu
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

6.  Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain.

Authors:  N E Richardson; N R Brown; R E Hussey; A Vaid; T J Matthews; D P Bolognesi; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.

Authors:  N R Landau; M Warton; D R Littman
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

8.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.

Authors:  D H Smith; R A Byrn; S A Marsters; T Gregory; J E Groopman; D J Capon
Journal:  Science       Date:  1987-12-18       Impact factor: 47.728

9.  Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein.

Authors:  B A Jameson; P E Rao; L I Kong; B H Hahn; G M Shaw; L E Hood; S B Kent
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

10.  A soluble form of CD4 (T4) protein inhibits AIDS virus infection.

Authors:  K C Deen; J S McDougal; R Inacker; G Folena-Wasserman; J Arthos; J Rosenberg; P J Maddon; R Axel; R W Sweet
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

View more
  14 in total

1.  Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

Authors:  A L Edinger; C Blanpain; K J Kunstman; S M Wolinsky; M Parmentier; R W Doms
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells.

Authors:  H Kaneko; L P Neoh; N Takeda; H Akimoto; T Hishikawa; H Hashimoto; S Hirose; S Karaki; M Takiguchi; H Nakauchi; Y Kaneko; N Yamamoto; I Sekigawa
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.

Authors:  Xilin Wu; Jia Guo; Mengyue Niu; Minghui An; Li Liu; Hui Wang; Xia Jin; Qi Zhang; Ka Shing Lam; Tongjin Wu; Hua Wang; Qian Wang; Yanhua Du; Jingjing Li; Lin Cheng; Hang Ying Tang; Hong Shang; Linqi Zhang; Paul Zhou; Zhiwei Chen
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

7.  Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.

Authors:  Q J Sattentau; J P Moore; F Vignaux; F Traincard; P Poignard
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 8.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

9.  Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.

Authors:  J McKeating; P Balfe; P Clapham; R A Weiss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.

Authors:  S Matsushita; S Matsumi; K Yoshimura; T Morikita; T Murakami; K Takatsuki
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.